Garetosmab for Children with Fibrodysplasia Ossificans Progressiva
Part of Bones, joints & muscles clinical trials.
This study tests whether garetosmab, a new medication, can slow or stop abnormal bone formation in children with FOP (a rare condition where muscle and connective tissue gradually turn into bone). The goal is to help young people with FOP move better and have fewer joint limitations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 4 and 18 years old (or 2 to 18 if outside the USA)
- You have been diagnosed with FOP by a doctor
- You weigh more than 30 kg (66 pounds), or the study has a special group for children 30 kg or less
- You do not have severe joint involvement from FOP (specific score of 19 or less)
- You have not had cancer in the past
- You do not have serious lung problems or a history of severe bleeding that needed a blood transfusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
This trial tests a gene therapy that uses a child's own stem cells to treat autosomal recessive osteopetrosis (a genetic bone disease). It aims to improve bone health and reduce complications like fractures and vision loss.
Hear when a new Fibrodysplasia Ossificans Progressiva (FOP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.